References
Adderley NJ, Ryan R, Nirantharakumar K, & Marshall T (2018). Prevalence and treatment of atrial fibrillation in UK general practice from 2000 to 2016. Heart (British Cardiac Society).
Admassie E, Chalmers L, & Bereznicki LR (2017). Changes in oral anticoagulant prescribing for stroke prevention in patients with atrial fibrillation. The American journal of cardiology 120:1133-1138.
Aguilar MI, & Hart R (2005). Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database of Systematic Reviews.
Alamneh EA, Chalmers L, & Bereznicki LR (2017). The Tasmanian Atrial Fibrillation Study: Transition to direct oral anticoagulants 2011-2015. Cardiovascular therapeutics 35.
Australian Bureau of Statistics (2018). Socio-Economic Indexes for Areas (SEIFA). Australian Bureau of Statistics.
Australian Statistical Geography Standard (ASGS) (2017). Significant urban areas, urban centres and localities, section of state, July 2016. Australian Bureau of Statistics.
Busingye D, Gianacas C, Pollack A, Chidwick K, Merrifield A, Norman S, et al. (2019). Data Resource Profile: MedicineInsight, an Australian national primary health care database. Int J Epidemiol 48: 1741-1741h.
Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. (2010). Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European heart journal 31:2369-2429.
Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. (2012). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation–developed with the special contribution of the European Heart Rhythm Association. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 14:1385-1413.
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. The New England journal of medicine 361:1139-1151.
Drug Utilisation Sub-Committee (DUSC) (June 2016). Novel oral anticoagulant: predicted vs actual analysisNational Prescribing Service.
Gadsboll K, Staerk L, Fosbol EL, Sindet-Pedersen C, Gundlund A, Lip GYH, et al. (2017). Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark. European heart journal 38: 899-906.
Gonzalez-Chica DA, Vanlint S, Hoon E, & Stocks N (2018). Epidemiology of arthritis, chronic back pain, gout, osteoporosis, spondyloarthropathies and rheumatoid arthritis among 1.5 million patients in Australian general practice: NPS MedicineWise MedicineInsight dataset. BMC musculoskeletal disorders 19: 20.
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. (2011). Apixaban versus warfarin in patients with atrial fibrillation. The New England journal of medicine 365:981-992.
Loo SY, Dell’Aniello S, Huiart L, & Renoux C (2017). Trends in the prescription of novel oral anticoagulants in UK primary care. British journal of clinical pharmacology 83: 2096-2106.
McHugh ML (2012). Interrater reliability: the kappa statistic. Biochem Med (Zagreb) 22: 276-282.
MedicineInsight (2018). MedicineInsight data book and data dictionary
NPS MedicineWise: Sydney.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al.(2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England journal of medicine 365: 883-891.
Pol D, Curtis C, Ramukumar S, & Bittinger L (2018). NOACs now mainstream for the use of anticoagulation in non-valvular atrial fibrillation in Australia. Heart, lung & circulation.
Radford J, Kitsos A, Stankovich J, Castelino R, Khanam M, Jose M, et al. (2018). The epidemiology of chronic kidney disease in Australian general practice: National Prescribing Service MedicineWise MedicineInsight dataset. Nephrology.
Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. (2018). The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European heart journal 39: 1330-1393.
Yoon M, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, et al. (2018). Dynamic Changes of CHA2DS2-VASc Score and the Risk of Ischaemic Stroke in Asian Patients with Atrial Fibrillation: A Nationwide Cohort Study. Thromb Haemost 118: 1296-1304.